2012-5-6--Tianjin CanSino Biotechnology Inc. and Aeras, a US-based non-profit, today announced a collaboration to advance the development of CanSino’s tuberculosis vaccine candidate. TB continues to be a major threat to global health, causing 1.4 million deaths worldwide annually. According to the terms of the agreement, Aeras will provide financial and technical support for CanSino’s non-human primate proof-of-concept study in China. More details…
